BOA Young Investigator Award
BOA1 – BOA25
- BOA1: Natural Killer cell interaction with colorectal cancer lymph node metastases
- BOA2: High resolution array Comparative Genomic Hybridization (aCGH) of breast carcinoma identifies Mouse Double Minutes 4 (Mdm4) as one of the early genetic changes in breast cancer development: Mdm4 is a new independent prognostic and predictive marker
- BOA3: The need for a biological grading system and its relationship to the current Nottingham histological grading system (NGS)
- BOA4: Benefit of radiotherapy dose escalation in localized prostate cancer with respect to expression of intrinsic markers of hypoxia
- BOA5: Single photon emission computerised tomography and gamma scinitigraphy to track the migration of peri-tumourally administered dendritic cells
- BOA6: Tumour antigens can be successfully encapsulated within and efficiently delivered to dendritic cells by biopolymer nanoparticles
- BOA7: Role of radiotherapy in uterine sarcoma: 20 year experience at a single institution
- BOA8: Cervical cancer risk factors, feasibility and acceptability of visual inspection with acetic acid screening method in Sudan: a pilot study
- BOA9: Tablet burden in women with metastatic breast cancer (MBC): implications for clinical practice
- BOA10: Communicating the results of randomised clinical trials: do cancer patients understand multi-dimensional patient reported outcomes?
- BOA11: Encouraging early presentation of oral cancer in a high-risk group
- BOA12: Factors affecting attitudes towards colorectal cancer screening in the primary care population
- BOA13: Analysis of copy number alterations in familial and sporadic clear cell renal cell carcinoma with high resolution SNP arrays
- BOA14: Randomised controlled trial of early enteral nutrition (EEN) versus conventional management (CON) in patients undergoing major resection for upper gastrointestinal cancer
- BOA15: Assessing the effects of implementing the MASCC (Multinational Association of Supportive Care in Cancer) antiemetic guideline on the severity of nausea and vomiting following platinum chemotherapy
- BOA16: Complementary RNA interference and compound screens to identify novel therapeutic targets for mismatch repair deficient cancers
- BOA17: First-in-man, first-in-class, pharmacokinetic and pharmacodynamic phase I clinical trial of a human monoclonal antibody CNTO888 to CC-Chemokine Ligand 2 (CCL2/MCP-1) in patients with advanced solid tumours
- BOA18: NG2 expression identifies a cell population capable of maintaining tumour growth in glioblastoma
- BOA19: A radiosensitivity screen of a siRNA library of DNA repair genes identifies DNA polymerase theta as a tumour specific radiosensitiser
- BOA20: A transcriptomic and genomic investigation into taxane resistant breast cancer
- BOA21: Asymmetric division in stem cells of gut epithelium is lost in precancerous tissue
- BOA22: Anti-stem cell factor enhances the effect of anthracycline and taxane chemotherapy in chemoresistant breast cancer cell lines
- BOA23: ADAM-17 is a key regulator of ErbB survival response in colorectal cancer.
- BOA24: A microRNA prognostic signature for pancreatic ductal adenocarcinoma
- BOA25: Expression of inflammatory chemokine receptor CXCR4 plays an active role in metastatic malignant melanoma and is a viable therapeutic target
